These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17346208)

  • 1. Targeting bacterial secretion systems: benefits of disarmament in the microcosm.
    Baron C; Coombes B
    Infect Disord Drug Targets; 2007 Mar; 7(1):19-27. PubMed ID: 17346208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilicides-small molecules targeting bacterial virulence.
    Aberg V; Almqvist F
    Org Biomol Chem; 2007 Jun; 5(12):1827-34. PubMed ID: 17551629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-Molecule Inhibitors of the Type III Secretion System.
    Gu L; Zhou S; Zhu L; Liang C; Chen X
    Molecules; 2015 Sep; 20(9):17659-74. PubMed ID: 26404233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivirulence drugs to target bacterial secretion systems.
    Baron C
    Curr Opin Microbiol; 2010 Feb; 13(1):100-5. PubMed ID: 20079679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disarming the invader.
    Young GM
    Chem Biol; 2003 Mar; 10(3):204-5. PubMed ID: 12670533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical biology applied to the study of bacterial pathogens.
    Anthouard R; DiRita VJ
    Infect Immun; 2015 Feb; 83(2):456-69. PubMed ID: 25404026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical attenuation of pilus function and assembly in Gram-negative bacteria.
    Lo AW; Moonens K; Remaut H
    Curr Opin Microbiol; 2013 Feb; 16(1):85-92. PubMed ID: 23434114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Block Bacterial Pathogenesis by Interference with Motility and Chemotaxis.
    Erhardt M
    Curr Top Microbiol Immunol; 2016; 398():185-205. PubMed ID: 27000091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type III secretion: the bacteria-eukaryotic cell express.
    Mota LJ; Sorg I; Cornelis GR
    FEMS Microbiol Lett; 2005 Nov; 252(1):1-10. PubMed ID: 16216444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for the development and use of gram-negative bacterial virulence protein secretion inhibitors for prophylaxis and treatment of infectious diseases.
    Felise HB; Miller SI
    Crit Rev Immunol; 2010; 30(1):69-77. PubMed ID: 20370621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural biology of bacterial secretion systems in gram-negative pathogens--potential for new drug targets.
    Durand E; Verger D; Rêgo AT; Chandran V; Meng G; Fronzes R; Waksman G
    Infect Disord Drug Targets; 2009 Nov; 9(5):518-47. PubMed ID: 19594425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inhibitor of gram-negative bacterial virulence protein secretion.
    Felise HB; Nguyen HV; Pfuetzner RA; Barry KC; Jackson SR; Blanc MP; Bronstein PA; Kline T; Miller SI
    Cell Host Microbe; 2008 Oct; 4(4):325-36. PubMed ID: 18854237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecules That Sabotage Bacterial Virulence.
    Johnson BK; Abramovitch RB
    Trends Pharmacol Sci; 2017 Apr; 38(4):339-362. PubMed ID: 28209403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type III bacterial secretion system, a promising target for the development of a new generation of antibiotic drugs].
    Gintsburg AL; Zigangirova NA; Zorina VV
    Vestn Ross Akad Med Nauk; 2008; (10):34-9. PubMed ID: 19140396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads.
    González-Prieto C; Lesser CF
    Curr Opin Microbiol; 2018 Feb; 41():1-7. PubMed ID: 29141238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of an Antivirulence Agent Targeting HlyU-Regulated Virulence in
    Imdad S; Chaurasia AK; Kim KK
    Front Cell Infect Microbiol; 2018; 8():152. PubMed ID: 29868508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of type III secretion systems.
    Francis MS; Wolf-Watz H; Forsberg A
    Curr Opin Microbiol; 2002 Apr; 5(2):166-72. PubMed ID: 11934613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of proteins and assembly of bacterial surface organelles: shared pathways of extracellular protein targeting.
    Lory S
    Curr Opin Microbiol; 1998 Feb; 1(1):27-35. PubMed ID: 10066461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump.
    Abdali N; Parks JM; Haynes KM; Chaney JL; Green AT; Wolloscheck D; Walker JK; Rybenkov VV; Baudry J; Smith JC; Zgurskaya HI
    ACS Infect Dis; 2017 Jan; 3(1):89-98. PubMed ID: 27768847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.